---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-23-000670"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:53:12.105053+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Chemomab reports FY2022 net loss of $27.6M; cash runway through March 2024

## Summary
- Net loss of $27.6M in 2022 vs $12.5M in 2021; R&D expenses rose 168% to $17.0M.
- Cash used in operations was $20.4M; cash, equivalents and deposits fund operations through March 31, 2024.
- Phase 2 PSC trial actively recruiting; added 20mg/kg dose arm and open-label extension.
- Phase 2 SSc trial planned for H1 2023; completed NASH trial met safety endpoint with encouraging biomarker activity.
- No revenue from product sales; accumulated deficit of $64M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001178913-23-000670
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/zk2329164.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-23-000670
- JSON: https://secwatch.observer/filing/0001178913-23-000670.json
- Plain text: https://secwatch.observer/filing/0001178913-23-000670.txt

## Key facts
- Earnings Releases
  Chemomab Therapeutics Ltd. reported financial results for fiscal year ended December 31, 2022.
  - Period: fiscal year ended December 31, 2022
  - Result: reported results
  source text: Chemomab Therapeutics Ltd. (“we,” “us,” “our,” or the “Company”) is disclosing its consolidated audited financial statements for the fiscal year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534248/000117891323000670/0001178913-23-000670-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.